Shares of Sareum Holdings Plc (LON: SAR) are up 491% this year largely due to the pharmaceutical company’s involvement in creating a drug to combat the most severe respiratory symptoms of COVID-19 and other viral infections.
The company recently received a £174,000 grant from the UK Research & Innovation (UKRI) to investigate the therapeutic potential of its SDC-1801 selective, small molecule TYK2/JAK1 kinase inhibitor to treat coronavirus.
John Reader, Sareum’s CEO said: “We are delighted that UKRI has indicated its conditional support for our programme to investigate the therapeutic potential of SDC-1801, our proprietary TYK2/JAK1 inhibitor, in severe phase [coronavirus]”
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Some investors may be wondering whether they should buy Sareum shares given their rally this year. Well, I’d like to point out that Sareum does not yet have a drug that is ready being sold in the market yet, and we could see a major rally in the stock once such a drug hits the market.
However, it might take a while for the SDC-1801 drug candidate to go through clinical trials and get regulatory approval for human use; we could get a major rally on such news.
Investors interested in the stock should keep this in mind when deciding whether or not to buy the company’s shares.
Sareum share price
People who read this also read:
